D. Gaudet

D. Gaudet, G. Iotti, E. Steinhagen-Thiessen, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management.

D. Gaudet, I. Goldberg, W. Brown, 2018, Journal of clinical lipidology.

Roundtable on etiology of familial chylomicronemia syndrome.

D. Gaudet, R. Hegele, I. Goldberg, 2017, Journal of clinical lipidology.

Natural History (up to 15 years) of Platelet Count in 84 Patients with Familial Hyperchylomicronemia Due to Lipoprotein Lipase Deficiency

D. Gaudet, D. Brisson, K. Tremblay, 2017 .

Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of Lipidologist

D. Gaudet, M. Malloy, E. Bruckert, 2016 .

Apolipoprotein C-III Inhibition with Volanesorsen in Patients with Hypertriglyceridemia (COMPASS): a Randomized, Double-Blind, Placebo-controlled Trial

D. Gaudet, E. Steinhagen-Thiessen, I. Gouni-Berthold, 2017, Atherosclerosis Supplements.

The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS).

D. Gaudet, Joann D Flaim, L. Hemphill, 2017, Atherosclerosis.

Comparison of three methods for LDLC calculation for cardiovascular disease risk categorization in three distinct patient populations.

D. Gaudet, D. Brisson, T. Ooi, 2022, The Canadian journal of cardiology.

Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.

G. Francis, D. Gaudet, R. Hegele, 2018, Clinical chemistry.

Gene-based therapies in lipidology: current status and future challenges

D. Gaudet, D. Brisson, 2015, Current opinion in lipidology.

Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.

D. Gaudet, S. Kathiresan, R. Rosenson, 2014, Journal of the American College of Cardiology.

Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency.

D. Gaudet, D. Brisson, K. Tremblay, 2010, Atherosclerosis. Supplements.

Metabolic syndrome and oral markers of cardiometabolic risk.

D. Gaudet, D. Brisson, M. Tremblay, 2011, Journal.

Association between salivary pH and metabolic syndrome in women: a cross-sectional study

D. Gaudet, D. Brisson, M. Tremblay, 2012, BMC Oral Health.

Association between salivary pH and metabolic syndrome in women: a cross-sectional study

D. Gaudet, D. Brisson, M. Tremblay, 2012, BMC oral health.

Glycerol: a neglected variable in metabolic processes?

D. Gaudet, D. Brisson, M. Vohl, 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

Salivary pH as a marker of plasma adiponectin concentrations in Women

D. Gaudet, D. Brisson, J. Méthot, 2012, Diabetology & Metabolic Syndrome.

Community Genetics in Eastern Québec: The Experience of the Corporation for Research and Action on Hereditary Diseases

D. Gaudet, D. Brisson, A. Vigneault, 2001, Public Health Genomics.

Segment of Rat Chromosome 20 Regulates Diet-Induced Augmentations in Adiposity, Glucose Intolerance, and Blood Pressure

D. Gaudet, Z. Pausova, P. Hamet, 2003, Hypertension.

Role of tumor necrosis factor-alpha gene locus in obesity and obesity-associated hypertension in French Canadians.

D. Gaudet, Z. Pausova, P. Hamet, 2000, Hypertension.

Association testing of common variants in the insulin receptor substrate-1 gene (IRS1) with type 2 diabetes

M. Daly, D. Altshuler, J. Hirschhorn, 2007, Diabetologia.

Association testing in 9,000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with type 2 diabetes.

M. Daly, T. Hudson, D. Altshuler, 2004, Diabetes.

Genetic Variation in the Familial Mediterranean Fever Gene (MEFV) and Risk for Crohn's Disease and Ulcerative Colitis

T. Hudson, J. Rioux, E. Nimmo, 2009, PloS one.

Haplotype structures and large-scale association testing of the 5 ' AMP-activated protein kinase genes PRK4A2, PRKAB1, and PRK4B1 with type 2 diabetes

M. Daly, D. Altshuler, J. Hirschhorn, 2006 .

Visceral obesity attenuates the effect of the hepatic lipase -514C>T polymorphism on plasma HDL-cholesterol levels in French-Canadian men.

J. Després, D. Gaudet, M. Vohl, 2003, Molecular genetics and metabolism.

5' flanking variants of resistin are associated with obesity.

Scott M. Williams, T. Hudson, D. Altshuler, 2002, Diabetes.

Prenatal exposure to cigarette smoke interacts with OPRM1 to modulate dietary preference for fat.

T. Paus, D. Gaudet, G. Leonard, 2015, Journal of psychiatry & neuroscience : JPN.

Common variants in the NLRP3 region contribute to Crohn's disease susceptibility

Mathieu Lemire, Albert Cohen, Thomas J. Hudson, 2009, Nature Genetics.

Identification of a chromosome 8p locus for early-onset coronary heart disease in a French Canadian population

Swneke D. Bailey, T. Hudson, J. Rioux, 2008, European Journal of Human Genetics.

Evaluation of Common Variants in the Six Known Maturity-Onset Diabetes of the Young (MODY) Genes for Association With Type 2 Diabetes

Kristin G Ardlie, Wendy Winckler, Mark Walker, 2007, Diabetes.

Association of common variation in the HNF1alpha gene region with risk of type 2 diabetes.

Kristin G Ardlie, Wendy Winckler, Peter Almgren, 2005, Diabetes.

Association testing of variants in the hepatocyte nuclear factor 4alpha gene with risk of type 2 diabetes in 7,883 people.

M. Daly, T. Hudson, D. Altshuler, 2005, Diabetes.

Association Studies of BMI and Type 2 Diabetes in the Neuropeptide Y Pathway

Catarina D. Campbell, J. Hirschhorn, L. Groop, 2007, Diabetes.

Opioid receptor mu 1 gene, fat intake and obesity in adolescence

C. Greenwood, T. Paus, D. Gaudet, 2014, Molecular Psychiatry.

Novel genetic locus of visceral fat and systemic inflammation.

T. Paus, D. Gaudet, Z. Pausova, 2019, The Journal of clinical endocrinology and metabolism.

Emerging Genome Engineering Tools in Crop Research and Breeding.

D. Gaudet, J. Laurie, A. Bilichak, 2020, Methods in molecular biology.

Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia.

T. Hudson, J. Després, D. Gaudet, 2000, Journal of lipid research.

Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study.

D. Gaudet, M. Banach, J. López-Sendón, 2020, European journal of preventive cardiology.

Relative effect of hypertriglyceridemia on non-HDLC and apolipoprotein B as cardiovascular disease risk markers.

D. Gaudet, D. Brisson, T. Ooi, 2020, Journal of clinical lipidology.

Association of common gene-smoking interactions with elevated plasma apolipoprotein B concentration

D. Gaudet, D. Brisson, G. Tremblay, 2020, Lipids in Health and Disease.

Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in Hypertriglyceridemia

D. Gaudet, D. Brisson, T. Ooi, 2019, Journal of the Endocrine Society.

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study.

D. Gaudet, S. Gidding, F. Raal, 2018, Journal of clinical lipidology.

Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.

G. Francis, D. Gaudet, R. Hegele, 2018, Atherosclerosis.

Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia

D. Gaudet, E. Bruckert, C. Gagné, 2002, Circulation.

Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia

Johannes B. Reitsma, G. Kees Hovingh, D. Gaudet, 2016, European heart journal.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Lesley Burgess, Russell Scott, Rob Scott, 2015, The Lancet.

A largely random AAV integration profile after LPLD gene therapy

Stephan Wolf, Raffaele Fronza, Hanno Glimm, 2013, Nature Medicine.

From Community Genetics to Community Genomics: The Quebec Experience

T. Hudson, D. Gaudet, C. Laberge, 2001, Public Health Genomics.

Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia

D. Gaudet, D. Brisson, G. Tremblay, 2020, Journal of clinical medicine.

Simvastatin with or without ezetimibe in familial hypercholesterolemia.

A. Zwinderman, D. Gaudet, J. Kastelein, 2008, The New England journal of medicine.

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology

Jean-Claude Tardif, Frank M. Sacks, Robert A. Hegele, 2018, Nature Reviews Cardiology.

The Krüppel-Like Factor 11 (KLF11) Q62R Polymorphism Is Not Associated With Type 2 Diabetes in 8,676 People

M. Daly, D. Altshuler, J. Hirschhorn, 2006, Diabetes.

Genomewide linkage analysis of stature in multiple populations reveals several regions with evidence of linkage to adult height.

E. Lander, D. Altshuler, T. Hudson, 2001, American journal of human genetics.

PPARGC1α gene DNA methylation variations in human placenta mediate the link between maternal hyperglycemia and leptin levels in newborns

D. Gaudet, D. Brisson, J. Baillargeon, 2016, Clinical Epigenetics.

A variant near DHCR24 associates with microstructural properties of white matter and peripheral lipid metabolism in adolescents

T. Paus, D. Gaudet, Z. Pausova, 2020, Molecular Psychiatry.

Development and Optimization of a Germination Assay and Long-Term Storage for Cannabis sativa Pollen

D. Gaudet, N. Yadav, I. Kovalchuk, 2020, bioRxiv.

Sex differences in blood pressure and its relationship to body composition and metabolism in adolescence.

T. Paus, D. Gaudet, G. Leonard, 2009, Archives of pediatrics & adolescent medicine.

Clustering of the Metabolic Syndrome Components in Adolescence: Role of Visceral Fat

T. Paus, D. Gaudet, G. Leonard, 2013, PloS one.

Sex Differences in the Contributions of Visceral and Total Body Fat to Blood Pressure in Adolescence

T. Paus, D. Gaudet, G. Leonard, 2012, Hypertension.

Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.

D. Gaudet, R. Hegele, E. Bruckert, 2017, Journal of clinical lipidology.

Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis.

D. Gaudet, D. Brisson, G. Iotti, 2016, Human gene therapy.

Dyslipidemia of Mothers With Familial Hypercholesterolemia Deteriorates Lipids in Adult Offspring

D. Gaudet, D. Brisson, S. Sivapalaratnam, 2010, Arteriosclerosis, thrombosis, and vascular biology.

Reply to: NGS library preparation may generate artifactual integration sites of AAV vectors

Raffaele Fronza, Manfred Schmidt, Hanno Glimm, 2014, Nature Medicine.

High-density haplotype structure and association testing of the insulin-degrading enzyme (IDE) gene with type 2 diabetes in 4,206 people.

M. McCarthy, M. Daly, D. Altshuler, 2006, Diabetes.

Health supervision and anticipatory guidance in adult myotonic dystrophy type 1

D. Gaudet, P. Bégin, S. Veillette, 2010, Neuromuscular Disorders.

A phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia

D. Gaudet, D. Rader, C. Ballantyne, 2021, Atherosclerosis.

Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients With Hypercholesterolemia

S. Melquist, J. Knowles, D. Gaudet, 2020 .

Glycerol as a correlate of impaired glucose tolerance: dissection of a complex system by use of a simple genetic trait.

J. Rioux, J. Després, D. Gaudet, 2000, American journal of human genetics.

The potential applications of Apolipoprotein E in personalized medicine

D. Gaudet, D. Brisson, S. Villeneuve, 2014, Front. Aging Neurosci..

Layered genetic control of DNA methylation and gene expression: a locus of multiple sclerosis in healthy individuals.

Michael D. Wilson, M. Waldenberger, T. Paus, 2015, Human molecular genetics.

Contribution of Hierarchical Clustering Techniques to the Modeling of the Geographic Distribution of Genetic Polymorphisms Associated with Chronic Inflammatory Diseases in the Québec Population

D. Gaudet, C. Laprise, L. Pérusse, 2007, Public Health Genomics.

Variants within the muscle and liver isoforms of the carnitine palmitoyltransferase I (CPT1) gene interact with fat intake to modulate indices of obesity in French-Canadians

D. Gaudet, L. Pérusse, M. Vohl, 2007, Journal of Molecular Medicine.

Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases

Marie-France Hivert, Luigi Bouchard, D. Gaudet, 2013, Epigenetics.

Myotonic Dystrophy: Linkage with Apolipoprotein E and Estimation of the Gene Carrier Status with Genetic Markers

J. Morissette, D. Gaudet, C. Laberge, 1989, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Genome-Wide Scan for Linkage to Obesity-Associated Hypertension in French Canadians

T. Hudson, D. Gaudet, Z. Pausova, 2005, Hypertension.

Systematic, Genome-Wide, Sex-Specific Linkage of Cardiovascular Traits in French Canadians

D. Gaudet, E. Merlo, S. Orlov, 2008, Hypertension.

Association testing of the protein tyrosine phosphatase 1B gene (PTPN1) with type 2 diabetes in 7,883 people.

M. Daly, T. Hudson, D. Altshuler, 2005, Diabetes.

Impact of adiponectin gene polymorphisms on plasma lipoprotein and adiponectin concentrations of viscerally obese men Published, JLR Papers in Press, November 16, 2004. DOI 10.1194/jlr.M400135-JLR200

J. Després, D. Gaudet, M. Vohl, 2005, Journal of Lipid Research.

Placental lipoprotein lipase DNA methylation alterations are associated with gestational diabetes and body composition at 5 years of age

D. Gaudet, D. Brisson, M. Hivert, 2017, Epigenetics.

Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway

D. Gaudet, R. Do, J. Engert, 2009, Clinical genetics.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Diane M. Miller, Natalia E. Shilkina, M. C. Cantero, 2018, Lancet.

Routine Clinical Measures of Adiposity as Predictors of Visceral Fat in Adolescence: A Population-Based Magnetic Resonance Imaging Study

T. Paus, D. Gaudet, G. Leonard, 2013, PloS one.

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease

D. Gaudet, D. Tribble, E. Stein, 2012, Circulation.

ADRB3 gene promoter DNA methylation in blood and visceral adipose tissue is associated with metabolic disturbances in men.

D. Gaudet, D. Brisson, M. Vohl, 2014, Epigenomics.

LRP1B, BRD2 and CACNA1D: new candidate genes in fetal metabolic programming of newborns exposed to maternal hyperglycemia.

D. Gaudet, D. Brisson, S. Ruchat, 2015, Epigenomics.

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Robert Dufour, D. Gaudet, E. Stein, 2012, The Lancet.

Epipolymorphisms within lipoprotein genes contribute independently to plasma lipid levels in familial hypercholesterolemia

D. Gaudet, D. Brisson, B. Lamarche, 2014, Epigenetics.

Cohort Profile: The Saguenay Youth Study (SYS).

Louis Richer, Suzanne Veillette, Zdenka Pausova, 2016, International journal of epidemiology.

Functional Variation in the Androgen-Receptor Gene Is Associated With Visceral Adiposity and Blood Pressure in Male Adolescents

Louis Richer, Suzanne Veillette, Zdenka Pausova, 2010, Hypertension.

Quantitative founder-effect analysis of French Canadian families identifies specific loci contributing to metabolic phenotypes of hypertension.

T. Hudson, J. Rioux, D. Gaudet, 2005, American journal of human genetics.

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

D. Gaudet, D. Rader, C. Ballantyne, 2023, Nature Medicine.

Association between the PPARα-L162V polymorphism and components of the metabolic syndrome

D. Gaudet, L. Pérusse, M. Vohl, 2004, Journal of Human Genetics.

The lipoprotein/lipid profile is modulated by a gene–diet interaction effect between polymorphisms in the liver X receptor-α and dietary cholesterol intake in French-Canadians

D. Gaudet, L. Pérusse, M. Vohl, 2007, British Journal of Nutrition.

K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population

T. Hudson, A. Montpetit, D. Gaudet, 2008, Human mutation.

Common Polymorphisms in the Promoter of the Visfatin Gene (PBEF1) Influence Plasma Insulin Levels in a French-Canadian Population

Swneke D. Bailey, T. Hudson, C. Bouchard, 2006, Diabetes.

Immunosuppression Modulates Immune Responses to AAV Capsid in Human Subjects Undergoing Intramuscular Gene Transfer for Lipoprotein Lipase Deficiency

D. Gaudet, K. High, F. Mingozzi, 2008 .

Prenatal Exposure to Maternal Cigarette Smoking and Accumulation of Intra‐abdominal Fat During Adolescence

T. Paus, D. Gaudet, G. Leonard, 2010, Obesity.

Development of a real-time immuno-PCR assay for the quantification of environmental contaminants

D. Gaudet, 2014 .

Genetics of symptom remission in outpatients with COVID-19

D. Gaudet, J. Tardif, M. Dubé, 2021, Scientific Reports.

Arterial Pressure, Left Ventricular Mass, and Aldosterone in Essential Hypertension

D. Gaudet, Z. Pausova, P. Hamet, 2001, Hypertension.

Glomerular hyperfiltration in hypertensive African Americans.

D. Gaudet, P. Hamet, R. Roman, 2000, Hypertension.

ABCA1 gene promoter DNA methylation is associated with HDL particle profile and coronary artery disease in familial hypercholesterolemia

D. Gaudet, D. Brisson, B. Lamarche, 2012, Epigenetics.

The pleiotropic expression of the myotonic dystrophy protein kinase gene illustrates the complex relationships between genetic, biological and clinical covariates of male aging

D. Gaudet, D. Brisson, M. Vohl, 2002, The aging male : the official journal of the International Society for the Study of the Aging Male.

Epigenetic and genetic variations at the TNNT1 gene locus are associated with HDL-C levels and coronary artery disease.

Y. Bossé, D. Gaudet, D. Brisson, 2016, Epigenomics.

Dietary Vitamin A and Visceral Adiposity: A Modulating Role of the Retinol-Binding Protein 4 Gene

T. Paus, D. Gaudet, G. Leonard, 2015, Lifestyle Genomics.

Angiographically-assessed coronary artery disease associates with HDL particle size in women.

J. Després, D. Gaudet, I. Lemieux, 2012, Atherosclerosis.

Hypertriglyceridemic waist: a simple clinical phenotype associated with coronary artery disease in women.

J. Després, D. Gaudet, I. Lemieux, 2012, Metabolism: clinical and experimental.

Effect of obesity on HDL and LDL particle sizes in carriers of the null P207L or defective D9N mutation in the lipoprotein lipase gene: the Québec LipD Study

D. Gaudet, P. Julien, B. Lamarche, 2003, International Journal of Obesity.

Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease.

J. Després, D. Gaudet, M. Vohl, 2002, The American journal of cardiology.

Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians.

J. Després, D. Gaudet, M. Vohl, 1998, The American journal of cardiology.

Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene.

J. Després, D. Gaudet, M. Vohl, 1998, Circulation.

Daniel Coronary Artery Disease in Men With Known Mutations in the LDL Receptor Gene Relationships of Abdominal Obesity and Hyperinsulinemia to Angiographically Assessed

J. Després, D. Gaudet, M. Vohl, 1998 .

Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy.

D. Gaudet, P. Couture, Jean-Philippe Drouin-Chartier, 2017, The Canadian journal of cardiology.

Transient expression of the β-glucuronidase gene in Cannabis sativa varieties

D. Gaudet, N. Yadav, I. Kovalchuk, 2020, Plant signaling & behavior.

Correlation between chylomicronemia diagnosis scores and post-heparin lipoprotein lipase activity.

D. Gaudet, D. Brisson, Jasmine Chebli, 2019, Clinical biochemistry.

Prenatal exposure to maternal cigarette smoking, amygdala volume, and fat intake in adolescence.

Deborah H. Schwartz, T. Paus, D. Gaudet, 2013, JAMA psychiatry.

Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol.

T. Hudson, A. Montpetit, D. Gaudet, 2007, American journal of human genetics.

Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice.

Stefan Lorkowski, Johanne Tremblay, Martin Biel, 2009, The Journal of clinical investigation.

Prevalence of Lifestyle Risk Factors in Myotonic Dystrophy Type 1

D. Gaudet, D. Brisson, C. Gagnon, 2013, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Identification of a Novel C5L2 Variant (S323I) in a French Canadian Family With Familial Combined Hyperlipemia

D. Gaudet, K. Cianflone, J. Engert, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Influence of Abdominal Obesity on the Lipid-Lipoprotein Profile in Apoprotein E2/4 Carriers: The Effect of an Apparent Duality

D. Gaudet, D. Brisson, S. Villeneuve, 2015, Journal of lipids.

Visceral fat enhances blood pressure reactivity to physical but not mental challenges in male adolescents

T. Paus, D. Gaudet, G. Leonard, 2015, Pediatric obesity.

Genetic epistasis in the VLDL catabolic pathway is associated with deleterious variations on triglyceridemia in obese subjects

T. Hudson, J. Després, D. Gaudet, 2007, International Journal of Obesity.

Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.

Y. Bossé, T. Hudson, D. Gaudet, 2002, Pharmacogenetics.

INVESTIGATING CLINICALLY-DEFINED SUBSETS OF HYPERTENSION MAY FACILITATE THE SEARCH FOR ITS GENES: 1B.5

D. Gaudet, Z. Pausova, P. Hamet, 2004 .

Sex Differences in Blood Pressure Hemodynamics in Middle-Aged Adults With Overweight and Obesity.

T. Paus, D. Gaudet, Z. Pausova, 2019, Hypertension.

Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study

D. Gaudet, H. Yang, C. Nilsson, 2020, Lipids in Health and Disease.

The burden of familial chylomicronemia syndrome in Canadian patients

D. Gaudet, G. Trentin, S. Bernard, 2020, Lipids in Health and Disease.

Fine mapping and association studies of a high-density lipoprotein cholesterol linkage region on chromosome 16 in French-Canadian subjects

Swneke D. Bailey, T. Hudson, J. Rioux, 2010, European Journal of Human Genetics.

A Common Variant of the FTO Gene Is Associated With Not Only Increased Adiposity but Also Elevated Blood Pressure in French Canadians

T. Paus, D. Gaudet, G. Leonard, 2009, Circulation. Cardiovascular genetics.

Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.

D. Gaudet, J. Tardif, C. Ballantyne, 2022, Journal of clinical lipidology.

Translating the Genomics Revolution: The Need for an International Gene Therapy Consortium for Monogenic Diseases

J. Joung, C. Barbas, A. Bogdanove, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.

Jennifer G. Robinson, D. Gaudet, G. Watts, 2015, The Journal of clinical endocrinology and metabolism.

A genealogical study of essential hypertension with and without obesity in French Canadians.

D. Gaudet, Z. Pausova, H. Vézina, 2002, Obesity research.

Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing

A. Morris, R. Gibbs, E. Boerwinkle, 2019, PloS one.

Adaptations of placental and cord blood ABCA1 DNA methylation profile to maternal metabolic status

D. Gaudet, D. Brisson, J. Baillargeon, 2013, Epigenetics.

Placental lipoprotein lipase DNA methylation levels are associated with gestational diabetes mellitus and maternal and cord blood lipid profiles

D. Gaudet, D. Brisson, J. Baillargeon, 2014, Journal of Developmental Origins of Health and Disease.

Genes, maternal smoking, and the offspring brain and body during adolescence: Design of the Saguenay Youth Study

Alain Pitiot, Alan C. Evans, Roberto Toro, 2007, Human brain mapping.

Abstract 17396: Apheresis Treatment does not Affect the Lipid-Lowering Efficacy of Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia

D. Gaudet, D. Rader, R. Hegele, 2012 .

Genealogical analysis as a new approach for the investigation of drug intolerance heritability

D. Gaudet, D. Brisson, M. Tremblay, 2013, European Journal of Human Genetics.

Large-scale deletions of the ABCA1 gene in patients with hypoalphalipoproteinemia[S]

D. Gaudet, R. Hegele, D. Brisson, 2018, Journal of Lipid Research.

Large-scale Deletions of the ABCA1 Gene in Patients with Hypoalphalipoproteinemia

D. Gaudet, R. Hegele, D. Brisson, 2018, Atherosclerosis Supplements.

Novel therapies for severe dyslipidemia originating from human genetics

D. Gaudet, 2016, Current opinion in lipidology.

Gestational Diabetes Mellitus Epigenetically Predominantly Affects Genes Involved in Metabolic Diseases

D. Gaudet, D. Brisson, S. Ruchat, 2013 .

On-site management of investigational products and drug delivery systems in conformity with Good Clinical Practices (GCPs)

D. Gaudet, D. Brisson, J. Méthot, 2012, Clinical trials.

Reduced Expression of Angiopoietin-Like Protein 3 via RNA Interference with ARO-ANG3 Produces Prolonged Reductions in LDL-C and Triglycerides in Dyslipidemic Patients

S. Melquist, J. Knowles, D. Gaudet, 2020 .

The Diacylglycerol Acyltransferase 1 Inhibitor, Pradigastat, Was Well Tolerated in a 52-Week Clinical Trial in FCS Patients

D. Gaudet, E. Stroes, Yinong Zhou, 2015 .

Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome

D. Gaudet, K. Tremblay, C. Meyers, 2015, Lipids in Health and Disease.

Effects of CER-001 on carotid atherosclerosis by 3tmri in homozygous familial hypercholesterolemia (HoFH): The modifying orphan disease evaluation (mode) study

D. Gaudet, E. Stroes, J. Paolini, 2014 .

Abstract 12594: Pharmacodynamic Effect of ARO-APOC3, an Investigational Hepatocyte-targeted RNA Interference Therapeutic Targeting Apolipoprotein C3, in Patients With Hypertriglyceridemia and Multifactorial Chylomicronemia

S. Melquist, J. Knowles, D. Gaudet, 2020 .

Efficacy of alirocumab in heterozygous familial hypercholesterolemia or high cv risk populations: pooled analyses of eight phase 3 trials

D. Gaudet, P. Minini, B. Cariou, 2015 .

Association study between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and metabolic syndrome

D. Gaudet, D. Brisson, M. Tremblay, 2018, BMC Medical Genetics.

A pilot study of MBX-8025 in the treatment of homozygous familial hypercholesterolemia (HoFH)

D. Gaudet, J. Tardif, S. Bergheanu, 2016 .

Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations.

J. Morissette, J. Després, D. Gaudet, 1999, Atherosclerosis.

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.

D. Gaudet, J. Kastelein, F. Mach, 2020, The New England journal of medicine.

Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles

D. Gaudet, R. Hegele, E. Bruckert, 2019, Journal of the Endocrine Society.

Medical resource use and costs associated with chylomicronemia

D. Gaudet, D. Brisson, K. Tremblay, 2013, Journal of medical economics.

Epigenome-wide analysis in familial hypercholesterolemia identified new loci associated with high-density lipoprotein cholesterol concentration.

Luigi Bouchard, Gregory Voisin, D. Gaudet, 2012, Epigenomics.

A study in familial hypercholesterolemia suggests reduced methylomic plasticity in men with coronary artery disease.

Luigi Bouchard, Y. Bossé, D. Gaudet, 2015, Epigenomics.

Ethical Issues in Molecular Screening for Heterozygous Familial Hypercholesterolemia: The Complexity of Dealing with Genetic Susceptibility to Coronary Artery Disease

D. Gaudet, S. Tonstad, P. Couture, 1999, Public Health Genomics.

Procedure to protect confidentiality of familial data in community genetics and genomic research

D. Gaudet, M. Bernard, P. Hamet, 1999, Clinical genetics.

Predictors of Target Organ Damage in Hypertensive Blacks and Whites

D. Gaudet, Z. Pausova, R. Hoffmann, 2001, Hypertension.

Atherosclerotic plaque regression in homozygous familial hypercholesterolaemia: a case report of a long-term lipid-lowering therapy involving LDL-receptor-independent mechanisms

D. Gaudet, F. Raal, J. Mancini, 2023, European heart journal. Case reports.

Statin Initiation: Guideline Concordance and Characteristics of New Users in Quebec, Canada

D. Gaudet, J. Tardif, M. Dubé, 2020, Journal of Population Therapeutics and Clinical Pharmacology.

T. Paus, D. Gaudet, G. Leonard, 2018, International Journal of Obesity.

Treatment with Volanesorsen (VLN) Reduced Triglycerides and Pancreatitis in Patients with FCS and sHTG vs Placebo: Results of the APPROACH and COMPASS †

D. Gaudet, E. Bruckert, E. Stroes, 2018 .

DNA methylation at LRP1 gene locus mediates the association between maternal total cholesterol changes in pregnancy and cord blood leptin levels

D. Gaudet, D. Brisson, J. Baillargeon, 2019, Journal of Developmental Origins of Health and Disease.

Association of common gene-smoking interactions with elevated plasma apolipoprotein B concentration

D. Gaudet, D. Brisson, G. Tremblay, 2020, Lipids in Health and Disease.

SARS–CoV-2 Receptor ACE2 Gene Is Associated with Hypertension and Severity of COVID 19: Interaction with Sex, Obesity, and Smoking

T. Paus, D. Gaudet, M. Abrahamowicz, 2021, American journal of hypertension.

Association of CTRC and SPINK1 gene variants with recurrent hospitalizations for pancreatitis or acute abdominal pain in lipoprotein lipase deficiency

D. Gaudet, D. Brisson, K. Tremblay, 2014, Front. Genet..

Dissection of Clinical and Gene Expression Signatures of Familial versus Multifactorial Chylomicronemia

D. Gaudet, D. Brisson, K. Tremblay, 2020, Journal of the Endocrine Society.

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

D. Gaudet, R. Hegele, F. Raal, 2023, European heart journal.

1.P.178 Effect of atorvastatin on serum levels of lipoproteins in French Canadians with homozygous or compound heterozygous familial hypercholesterolemia

D. Gaudet, P. Couture, J. Bergeron, 1997 .

T. Paus, D. Gaudet, Z. Pausova, 2020, Journal of neuroendocrinology.

CYP17A1 and Blood Pressure Reactivity to Stress in Adolescence

T. Paus, D. Gaudet, G. Leonard, 2015, International journal of hypertension.

Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study

D. Gaudet, H. Yang, M. Davidson, 2020, Lipids in Health and Disease.

4.P.114 Hyperinsulinemia and abdominal obesity in heterozygous familial lipoprotein lipase deficiency

J. Després, D. Gaudet, M. Vohl, 1997 .

Common Variants in the ENPP1 Gene Are Not Reproducibly Associated With Diabetes or Obesity

M. Daly, D. Altshuler, J. Hirschhorn, 2006, Diabetes.

A sequence variation in the mitochondrial glycerol-3-phosphate dehydrogenase gene is associated with increased plasma glycerol and free fatty acid concentrations among French Canadians.

T. Hudson, J. Després, D. Gaudet, 2001, Molecular genetics and metabolism.

Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population

Swneke D. Bailey, S. Yusuf, J. Bosch, 2013, Diabetes Care.

Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-RiskMulti-Ethnic Population The EpiDREAM Genetic Study

Swneke D. Bailey, J. Bosch, A. Montpetit, 2013 .

Association between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and hypertension

D. Gaudet, D. Brisson, M. Tremblay, 2016, Hypertension Research.

From DNA to the Community

Maria do Rosário Silva, A. Kent, D. Gaudet, 2000, Public Health Genomics.

Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE

D. Gaudet, M. Banach, J. López-Sendón, 2021, Archives of medical science : AMS.

A locus on chromosome 10 influences C-reactive protein levels in two independent populations

D. Gaudet, J. Erdmann, C. Hengstenberg, 2007, Human Genetics.

Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE.

D. Gaudet, D. Brisson, M. Paquette, 2017, Journal of clinical lipidology.

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts

S. Melquist, J. Knowles, D. Gaudet, 2023, Nature Medicine.

Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.

D. Gaudet, R. Hegele, E. Bruckert, 2017, Journal of clinical lipidology.

From Family to Pharmacogenetics

D. Gaudet, Z. Pausova, P. Hamet, 2001, Public Health Genomics.

Coronary Atheroma Regression From Infusions of Autologous Selectively Delipidated Preβ-HDL-Enriched Plasma in Homozygous Familial Hypercholesterolemia.

D. Gaudet, P. Shah, H. Brewer, 2020, Journal of the American College of Cardiology.

From clinical sites to biorepositories: effectiveness in blood sample management.

D. Gaudet, C. Lefebvre, M. Saghbini, 2010, Biopreservation and biobanking.

Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.

D. Gaudet, M. Arca, E. Stroes, 2023, Journal of clinical lipidology.

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.

D. Gaudet, M. Arca, S. Tsimikas, 2019, The New England journal of medicine.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

D. Gaudet, F. Raal, F. Civeira, 2015, The Lancet.

Post-prandial analysis of fluctuations in the platelet count and platelet function in patients with the familial chylomicronemia syndrome

D. Gaudet, D. Brisson, Marie-Claude Morissette, 2022, Orphanet Journal of Rare Diseases.

Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

J. Mckenney, D. Gaudet, E. Stein, 2014, The American journal of cardiology.

Epipolymorphisms within lipoprotein genes contribute independently to plasma lipid levels in familial hypercholesterolemia

D. Gaudet, D. Brisson, B. Lamarche, 2014, Epigenetics.

Epigenome-wide analysis in familial hypercholesterolemia identified new loci associated with high-density lipoprotein cholesterol concentration.

D. Gaudet, D. Brisson, G. Voisin, 2012, Epigenomics.

Increased frequency of DRB1*11:01 in anti–hydroxymethylglutaryl‐coenzyme A reductase–associated autoimmune myopathy

A. Mammen, D. Gaudet, D. Brisson, 2012, Arthritis care & research.

An Antisense Inhibitor of Apolipoprotein C-III Substantially Decreases Fasting Apolipoprotein C-III and Triglyceride Levels in LPL Deficiency

D. Gaudet, K. Tremblay, R. Geary, 2014 .

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

G. Francis, Qian Wang, D. Gaudet, 2021, Lancet.